No abstract

No abstract

Background Whole-body diffusion-weighted magnetic resonance imaging (WB-DWI-MRI) is an emerging tool that has an increasing role in the diagnosis of metastasis and lymphoma. This is a longitudinal study in actual clinical settings designed to assess WB-DWI-MRI in detection of tumor spread. The study included all patients who were referred to Radiology Department, during the period from June 2016 till May 2018, with either a known primary tumor (either laboratory, radiologically, or histologically proven, of any type, affecting any organ) or with biopsy-proven lymphoma of any subtype, affecting any organ. All patients underwent WB coronal T1-weighted, STIR, axial T2-weighted, and DWI-MRI examinations before commencing any treatment with curative intent. The body was divided into lymph nodes (LNs), skeletal system, and organs (brain, lung, and liver). Patients were followed up till the nature of the lesion(s) was confirmed (clinically, radiologically, or histologically). Results The study included 46 patients; 27 patients had metastases and 19 had lymphomas. Sensitivities, specificities, and accuracies for LN detection were 77%, 85%, and 83%; for skeletal metastasis were 88%, 94%, and 92%; for brain lesions were 78%, 95%, and 91%; and for lung lesion were 64%, 88%, and 76%, respectively. As for the liver, all lesions were correctly identified and did not miss any lesion with accuracy of 100%. Overall, 1739 lesions were discovered in 1271 regions out of 3818 examined regions with overall sensitivity, specificity, and accuracy of 86%, 92%, and 90% respectively. Conclusion The diagnostic performance of WB-DWI-MRI is variable among different anatomical sites. It has good performance in diagnosis of some organs as liver, bone marrow, and some LNs regions as porta-hepatis. It has a less diagnostic performance in the lung, and LNs located in cervical, mediastinum, supraclavicular, and mesenteric regions.

No abstract

In interferon-free era, direct-acting antiviral agents (DAAs) have achieved high eradication rates with an excellent safety profile since revolutionized the management of hepatitis c virus (HCV) patients. Published papers have suggested a possible increased incidence of hepatocellular carcinoma (HCC) after successful DAAs treatment. Other papers have been published about the problem but without conclusive results. Because of this debate, we aim to evaluate the effects of antiviral therapy (Sofosbuvir plus Daclatasvir with or without Ribavirin) on the de novo occurrence of HCC in patients with liver cirrhosis (LC). Patients and Methods: A prospective cohort study has included 350 patients who have visited our center for HCV treatment. Pretreatment history, examination, complete blood picture, liver function tests, kidney function tests, HA1C for diabetic patients, HCV PCR, HBsAg, alpha-fetoprotein (AFP), and abdominal ultrasound have been done, also Child-Po gh (CP) and Model for End-Stage Liver Disease (MELD) score before treatment. These investigations have been repeated for 3 months after the end of treatment. Abdominal ultrasound (US) has been done for 3 months after treatment and every 4 months for 2 years after the end of treatment to detect HCC occurrence. Results: Patients age (58.11 ± 7.48), 55.4% of patients were males, 30.3% of patients were diabetic, 84.3% of them were treatment naïve and sustained virological response (SVR) occured in 94% of them. HCC occurrence after treatment was 6.7% in patients with SVR and 23.8% in patients with non-SVR (P value=0.016) during follow-up period. There is significant improvement of CP score. No significant changes in MELD score. Conclusion: Treatment of HCV-related LC patients with sofosbuvir and daclatasvir with or without ribavirin for 3 or 6 months showed high SVR and significant improvement in CP score, but still at risk of HCC even if treated and should be followed up regularly according to screening programs with special meticulous attention to those with non-SVR.